TrialAdvances in therapy2025

Anlotinib Plus Docetaxel is Promising in Advanced NSCLC Progressing on First-Line Immunotherapy: A Pooled Analysis of Two Randomized Trials.

Xingxiang Pu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.